An overview is given of the design of drugs which interfere with the folding mechanism of the target protein, destabilizing it and making it prone to proteolisis. It is shown that these drugs are efficient, specific, and do not suffer from the upraise of resistance
Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can ...
ABSTRACT: Acquired resistance to therapeutic agents is a significant barrier to the development of c...
involves the accumulation of multiple mutations in the protein. We investigate the role of these mut...
Learning how proteins fold will hardly have any impact on the way conventional — active site centere...
Learning how proteins fold will hardly have any impact on the way conventional — active site centere...
The main problems found in designing drugs are those of optimizing the drug–target interaction and o...
Human immunodeficiency virus type 1 (HIV-1) protease (PR) plays an essential role in the life cycle ...
Studies of protein folding indicate the presence of native contacts in the denatured state, giving r...
General physical principles have taught us that, good folders are those sequences of amino acids whi...
The invention relates to the design of inhibitors of the HIV-1-PR homodimer which do not create resi...
Inhibitors of proteolytic enzymes (proteases) are emerging as prospective treatments for diseases su...
Drug resistance is a major problem in health care, undermining therapy outcomes and necessitating no...
Molecular recognition is central to biology and ranges from highly selective to broadly promiscuous....
An exactly solvable model based on the topology of a protein native state is applied to identify bot...
A novel way to inhibit HIV-1 protease by destabilizing its native state is discussed. A simplified p...
Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can ...
ABSTRACT: Acquired resistance to therapeutic agents is a significant barrier to the development of c...
involves the accumulation of multiple mutations in the protein. We investigate the role of these mut...
Learning how proteins fold will hardly have any impact on the way conventional — active site centere...
Learning how proteins fold will hardly have any impact on the way conventional — active site centere...
The main problems found in designing drugs are those of optimizing the drug–target interaction and o...
Human immunodeficiency virus type 1 (HIV-1) protease (PR) plays an essential role in the life cycle ...
Studies of protein folding indicate the presence of native contacts in the denatured state, giving r...
General physical principles have taught us that, good folders are those sequences of amino acids whi...
The invention relates to the design of inhibitors of the HIV-1-PR homodimer which do not create resi...
Inhibitors of proteolytic enzymes (proteases) are emerging as prospective treatments for diseases su...
Drug resistance is a major problem in health care, undermining therapy outcomes and necessitating no...
Molecular recognition is central to biology and ranges from highly selective to broadly promiscuous....
An exactly solvable model based on the topology of a protein native state is applied to identify bot...
A novel way to inhibit HIV-1 protease by destabilizing its native state is discussed. A simplified p...
Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can ...
ABSTRACT: Acquired resistance to therapeutic agents is a significant barrier to the development of c...
involves the accumulation of multiple mutations in the protein. We investigate the role of these mut...
DOI
Add to ORKG